Article
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Apr 2020
Rosen Ezra Y, Goldman Debra A, Hechtman Jaclyn F, Benayed Ryma, Schram Alison M, Cocco Emiliano, Shifman Sophie, Gong Yixiao, Kundra Ritika, Solomon James P, Bardelli Alberto, Scaltriti Maurizio, Drilon Alexander, Iasonos Alexia, Taylor Barry S, Hyman David M
Abstract excerpt
PURPOSE: TRK inhibitors achieve marked tumor-agnostic efficacy in TRK fusion-positive cancers and consequently are now an established standard of care. Little is known, however, about the demographics, outcomes, response to alternative standard therapies, or genomic characteristics of TRK fusion-positive cancers. EXPERIMENTAL DESIGN: Utilizing a center-wide screening program involving more than 26,000...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.